Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Twist Bioscience Corp — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.01 (market cap $378.77M), while Twist Bioscience Corp trades at $162.88 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 26.6× JPMorgan Diversified Return International Eqty ETF's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, JPMorgan Diversified Return International Eqty ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 120 Days and Twist Bioscience Corp for 27 Days on average.
| JPIN | TWST | |
|---|---|---|
Market Cap | $378.77M | $10.08B |
Volume | 13,861 | 4,229,037 |
52-Week High | $77.80 | $205.00 |
52-Week Low | $64.96 | $25.45 |
Typical Hold Time | 120 Days | 27 Days |
Sector | — | Health |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.01, up 0.1% on the day, but technical indicators signal a bearish trend with 21 sell signals versus 2 buy signals. The ETF exhibits oversold conditions with RSI readings below 25, while moving averages and ADX reinforce downward momentum. A dividend of $0.51 is scheduled for payment in September 2026, offering income potential amid weak price action.
The outlook remains cautious due to strong bearish technical pressure, though oversold RSI levels may attract contrarian buyers. Risks include persistent selling pressure and reliance on international equity markets. Investment appeal hinges on dividend yield and potential mean reversion if broader market sentiment improves.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
